Collaboration combines Apellis’ expertise in complement, a complex biological system, with Beam’s proprietary base editing platform Companies will collaborate on six research programs directed to

NEW EPIDAREX PORTFOLIO COMPANY WILL DEVELOP NOVEL CYCLIC ASPIRATION SYSTEM TO REMOVE BLOOD CLOTS FROM THE BRAIN Bethesda, MD, June 23, 2021 — Epidarex Capital,

EMPAVELI demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization (p<0.0001) and reduction in lactate dehydrogenase (LDH) (p<0.0001) compared to standard of care, which

WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that

Funds will be used to advance pre-clinical and manufacturing development programmes and prepare for clinical studies. Leeds, UK, 13 May 2021: LUNAC Therapeutics (LUNAC), a

Seven accepted abstracts, including an oral presentation, reinforce the potential of pegcetacoplan, an investigational, targeted C3 therapy, to redefine treatment for patients with paroxysmal nocturnal

Marketing application for pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH) is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA target action

Post hoc analysis showed a 46% decrease in mean lesion growth in eight patients with bilateral GA comparing treated eye vs. untreated fellow eye at